Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exemestane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exemestane SCHEMBL178041 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172893 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL2233503 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL19452231 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6730580 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL13794245 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL1781618 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172860 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL21698489 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| SCHEMBL13301017 | 0.92 | CYP19A1 (0.84) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 78281 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026099483-A1 | A READY-TO-USE DRUG DELIVERY SYSTEM | SEVER PHARMA SOLUTIONS (SE) | 2026-05-15 | — | — | WO | claimed |
| WO-2026098706-A1 | USE IN TREATING BREAST CANCER AFTER TREATMENT WITH CDK4/6 INHIBITOR | 正大天晴药业集团股份有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026100645-A1 | METHODS FOR TREATING VASOMOTOR SYMPTOMS IN BREAST CANCER PATIENTS WITH FEZOLINETANT | ASTELLAS PHARMA INC. (JP) | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| CN-122005782-A | FBP1 agonist and PD-1/VEGF bispecific antibody composition and anti-tumor application thereof | 郑州大学第一附属医院 | 2026-05-12 | — | — | CN | claimed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | claimed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0480950-A1 | COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ENDORECHERCHE INC. (CA) | 1992-04-22 | — | — | EP | claimed |
| EP-0479570-A2 | Animal growth promotion with aromatase inhibitors | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | claimed |
| EP-0462189-A1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES. | ENDORECHERCHE INC (CA) | 1991-12-27 | — | — | EP | claimed |
| EP-0433084-A2 | Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry | MERCK & CO. INC. (US) | 1991-06-19 | — | — | EP | claimed |
| WO-1991000731-A1 | COMBINATION THERAPY FOR PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | claimed |
| WO-1990010462-A1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES | ENDORECHERCHE INC. (CA) | 1990-09-20 | — | — | WO | claimed |
| US-4808616-A | 6-substituted androsta-1,4-diene-3,17-diones | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-02-28 | — | — | US | claimed |
| EP-0253591-A1 | New 6- or 7-methylenandrosta-1, 4-diene-3,17-dione derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-01-20 | — | — | EP | claimed |